A study to test whether different combinations of BI 765063, ezabenlimab, chemotherapy, cetuximab, and BI 836880 help people with head and neck cancer or liver cancer
1443-0002
Phase 1 other active
Quick answer
A study to test whether different combinations of BI 765063, ezabenlimab, chemotherapy, cetuximab, and BI 836880 help people with head and neck cancer or liver cancer for head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma is a Phase 1 program (other) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma
- Phase
- Phase 1
- Modality
- other
- Status
- active